PDGFR Tyrosine Kinase Inhibitor III

IUN54940, also known as PDGFR Tyrosine Kinase Inhibitor III, is a PDGFR inhibitor.

PDGFR Tyrosine Kinase Inhibitor III (PDGF Receptor Tyrosine Kinase Inhibitor III), a multikinase inhibitor, inhibits PDGFR, EGFR, FGFR, PKA, and PKC, respectively. PDGFR Tyrosine Kinase Inhibitor III can be used for the research of amyotrophic lateral sclerosis[1].

ChEBI: PDGF receptor tyrosine kinase inhibitor III is an N-arylpiperazine that is piperazine in which the hydrogen attached to the nitrogen at position 1 is replaced by a (4-phenoxyphenyl)aminocarbonyl group, while the hydrogen attached to the nitrogen at position 4 is replaced by a 6,7-dimethoxyquinazolin-4-yl group. It is an inhibitor of tyrosine kinases FLT3, PDGFR and KIT. It has a role as an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor. It is a N-arylpiperazine, a N-carbamoylpiperazine, an aromatic ether, a member of phenylureas, a member of quinazolines and a tertiary amino compound.

[1] Young-Min Lee. Compositions and methods for zika virus characterization and vaccine development. WO2019204654A1.
[2] KENJI MATSUNO. Potent and Selective Inhibitors of Platelet-Derived Growth Factor Receptor Phosphorylation. 1. Synthesis, Structure−Activity Relationship, and Biological Effects of a New Class of Quinazoline Derivatives[J]. Journal of Medicinal Chemistry, 2002, 45 14: 3057-3066. DOI: 10.1021/jm010428o
[3] XIN-LONG YAN. Migration of dorsal aorta mesenchymal stem cells induced by mouse embryonic circulation[J]. Developmental Dynamics, 2010, 240 1: 65-74. DOI: 10.1002/dvdy.22490